Hexarelin: A Research Overview

Introduction

Hexarelin (International Nonproprietary Name: examorelin; development code EP-23905; CAS 140703-51-1) is a synthetic hexapeptide classified within the growth hormone-releasing peptide (GHRP) family of growth hormone secretagogues (GHS). Developed by Romano Deghenghi and colleagues at Europeptides (Argenteuil, France) in the early 1990s, hexarelin attracted substantial research interest as one of the most potent GH-releasing peptides characterized in its class. A further body of preclinical literature has examined hexarelin's interactions with cardiac and peripheral receptors operating independently of GH release — a dual-receptor pharmacology that continues to inform published research. This article provides an educational reference overview of hexarelin's chemical identity, pharmacological classification, and development history, based on published primary literature.

Background

The synthetic growth hormone-releasing peptide family emerged from observations by endocrinologist Cyril Bowers, whose laboratory reported in the late 1970s that certain enkephalin analogs displayed GH-releasing activity in rat pituitary cultures [1]. GHRP-6 was the first member of this family demonstrated to elicit dose-related GH release both in vitro and in vivo, establishing the structural template for subsequent analog development. Iterative structure-activity relationship studies over the following decade produced hexarelin, which incorporated a chemical modification to the tryptophan residue that conferred greater metabolic stability and increased receptor-binding potency relative to the parent scaffold [1]. A structurally distinct but pharmacologically related GH secretagogue developed in the same era is ipamorelin, which shares the same receptor target while differing in peptide length and receptor-binding profile.

A 2017 historical appraisal published in Clinical Medicine Insights: Cardiology reviewed the body of evidence supporting cytoprotective properties of the synthetic GHRP family and documented hexarelin's position within the developmental lineage of these compounds [1]. That review traced the expanding body of preclinical research identifying pharmacological activities beyond pituitary GH release, with hexarelin featuring prominently in the cardiovascular literature.

Chemistry and Structure

Hexarelin is a synthetic six-amino acid peptide (hexapeptide) with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂. Its molecular formula is C₄₇H₅₈N₁₂O₆, with a molecular weight of approximately 887 daltons. The C-terminus carries an amide group (NH₂) rather than a free carboxyl.

The compound's key structural distinction from its progenitor GHRP-6 is the substitution of D-tryptophan at position two with D-2-methyltryptophan (D-2-Me-Trp). Deghenghi and colleagues reported in 1994 that this modification confers enhanced resistance to enzymatic degradation and increases GH-releasing potency relative to the parent sequence [2]. The presence of non-standard D-amino acids at the second and fifth positions (D-2-Me-Trp and D-Phe, respectively) further contributes to proteolytic stability in biological environments.

Hexarelin has no structural homology with growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that stimulates GH secretion via a distinct receptor. This structural independence is pharmacologically significant: the two classes act through separate receptor systems and can produce additive effects when combined in experimental settings.

Pharmacological Classification

Hexarelin is classified as a synthetic growth hormone secretagogue — specifically a GHRP-subtype agonist at the ghrelin/GHS-R1a receptor. The principal pharmacological target is the growth hormone secretagogue receptor subtype 1a (GHS-R1a), a G protein-coupled receptor (GPCR) cloned and characterized in 1996 by Howard and colleagues [3]. The discovery of ghrelin in 1999 as the endogenous GHS-R1a ligand confirmed that hexarelin and other synthetic GHRPs act as pharmacological agonists at the receptor for a natural hormone with documented roles in GH regulation, appetite, and energy homeostasis. GHS-R1a is expressed in the anterior pituitary and hypothalamus, where its activation stimulates GH secretion, and in peripheral tissues including the heart, where it mediates non-neuroendocrine signaling.

A distinct line of research subsequently identified CD36 — a class B scavenger receptor expressed in cardiomyocytes, macrophages, and endothelial microvasculature — as a second, non-GHSR binding site for hexarelin and structurally related GHRPs [4]. The molecular details of both receptor-engagement pathways are examined in the hexarelin mechanism of action article. Photoaffinity cross-linking studies published in 2004 localized the hexarelin binding site within the CD36 extracellular domain [4]. This dual-receptor pharmacology has informed interpretation of cardiovascular effects observed in animal models that persisted in GHS-R1a-knockout preparations, providing a framework for GH-independent mechanisms in the published literature.

Hexarelin is further distinguished from ghrelin — the endogenous GHS-R1a ligand, a 28-amino acid acylated peptide isolated in 1999 — by its greater chemical stability, smaller size, and higher receptor-binding affinity in comparative assays.

Discovery History

The discovery of hexarelin is traceable to Deghenghi and colleagues at Europeptides, who reported the synthesis and initial pharmacological characterization of the compound — referred to in early publications under the designation EP-23905 — beginning in 1994 [2]. The underlying concept exploited structure-activity relationship work conducted across the GHRP family following Bowers' foundational observations [1], specifically the finding that 2-methyl substitution on the tryptophan residue produced a more stable and potent variant of GHRP-6.

Initial human pharmacology studies published in 1994–1995 documented the compound's GH-releasing activity following administration in human subjects, including comparisons with existing secretagogues [5]. Research groups at the University of Turin — where Ezio Ghigo and colleagues conducted extensive early clinical pharmacology — and the University of Milan contributed substantially to characterization of hexarelin's neuroendocrine profile in humans during the mid-1990s.

From the late 1990s through the present, research interest expanded considerably beyond pituitary effects. Preclinical investigations reported GH-independent effects in rodent ischemia models, establishing a distinct cardiovascular research frontier that has continued to generate published literature into the 2020s.

Regulatory Status

Hexarelin advanced to Phase II clinical investigation under the Europeptides development program for indications that included growth hormone deficiency and congestive heart failure. The compound's International Nonproprietary Name (INN) — examorelin — was assigned by the World Health Organization, formally acknowledging its pharmaceutical development status. Phase II investigation did not advance to Phase III, and hexarelin has not received marketing authorization from the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), or comparable authorities for any therapeutic indication in humans.

As a synthetic peptide in research-grade supply, hexarelin from SpartaLabs is classified as a research-use-only (RUO) material. It is listed on the World Anti-Doping Agency (WADA) Prohibited List under the category of peptide hormones, growth factors, related substances, and mimetics, reflecting its pharmacological class rather than any approved clinical application.

References

1. Granado M, Martín AI, López-Menduiña M, López-Calderón A, Villanúa MA. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 2017;11:1179546817694558. PMID: 28469471. PMC: PMC5392015. DOI: 10.1177/1179546817694558

2. Deghenghi R, Cananzi MM, Torsello A, Battisti C, Müller EE, Locatelli V. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. 1994;54(18):1321–1328. PMID: 7910650. DOI: 10.1016/0024-3205(94)00845-X

3. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977. PMID: 8688086. DOI: 10.1126/science.273.5277.974

4. Bodart V, Bouchard JF, McNicoll N, Escher E, Carrière P, Ghigo E, et al. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochemistry. 2004;43(18):5557–5565. PMID: 15176951. PMC: PMC1133797. DOI: 10.1021/bi0302085

5. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf). 1995;43(5):631–635. PMID: 7584696. DOI: 10.1111/j.1365-2265.1995.tb02929.x